Sign up for the premium plan and unlock all options
After purchasing the premium plan, you will unlock all information about drug prices and their availability.
Search
Listing 390341 - 390360 out of 505060 entries
| Country | ATC | Drug name | Drug form, strength, package | Price level | Price in € | Price in local currency | Therapeutic areas | Manufacturer / Importer |
|---|---|---|---|---|---|---|---|---|
| Saudi Arabia | (L01XA03) oxaliplatin | Xaliptine | 1 Vial, 10ml, 5 mg/ml, Intravenous use, Concentrate for solution for infusion, 5mg/ml , Vial, Concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
n/a | HEXALAG / FarevaUnterachGmbH |
| Saudi Arabia | (L01XA03) oxaliplatin | XALTIN 5MG/ML CONC. FOR SOLUTION FOR INFUSION (10ml) | 1 Vial, 10ml, 5 mg/ml, Intravenous use, Concentrate for solution for infusion, 5mg/ml , Vial, Concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
n/a | AccordHealthcareLimited / INTASPHARMACEUTICALSLIMITED |
| Saudi Arabia | (L01XA03) oxaliplatin | XALTIN 5MG/ML CONC. FOR SOLUTION FOR INFUSION (20ml) | 1 Vial, 20ml, 5 mg/ml, Intravenous use, Concentrate for solution for infusion, 5mg/ml , Vial, Concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
n/a | AccordHealthcareLimited / INTASPHARMACEUTICALSLIMITED |
| Saudi Arabia | (L01XC) monoclonal antibodies | BLINCYTO | 1 Vial, 35 µg, Intravenous use, Powder for concentrate for solution for infusion, 35µg , Vial, Powder for concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Precursor Cell Lymphoblastic Leukemia-Lymphoma | AmgenInc. / BoehringerIngelheimPharmaGmbH&Co.KG |
| Saudi Arabia | (L01XC02) rituximab | MABTHERA 10MG-1ML CONC. FOR I.V INFUSION | 2 Vial, 10ml, 10 mg/ml, Intravenous use, Concentrate and diluent for solution for infusion, 10mg/ml , Vial, Concentrate and diluent for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | ROCHE / RocheDiagnosticsGmbH |
| Saudi Arabia | (L01XC02) rituximab | Rixathon | 3 Vial, 10ml, 10 mg/ml, Intravenous use, Concentrate for solution for infusion, 10mg/ml , Vial, Concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Wegener Granulomatosis; Microscopic Polyangiitis; Pemphigus | SandozGmbH / LEKPHARMACEUTICALSD.D. |
| Saudi Arabia | (L01XC02) rituximab | MABTHERA 10MG-1ML CONC. FOR I.V INFUSION | 1 Vial, 50ml, 10 mg/ml, Intravenous use, Concentrate and diluent for solution for infusion, 10mg/ml , Vial, Concentrate and diluent for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | ROCHE / RocheDiagnosticsGmbH |
| Saudi Arabia | (L01XC02) rituximab | Rixathon | 2 Vial, 50ml, 10 mg/ml, Intravenous use, Concentrate for solution for infusion, 10mg/ml , Vial, Concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell; Wegener Granulomatosis; Microscopic Polyangiitis; Pemphigus | SANDOZGMBH / LEKPHARMACEUTICALSD.D. |
| Saudi Arabia | (L01XC02) rituximab | MABTHERA 120 MG/ML SOLUTION FOR SUBCUTANEOUS FOR INJECTION | 1 Vial, 11,7ml, 120 mg/ml, Subcutaneous use, Concentrate and diluent for solution for infusion, 120mg/ml , Vial, Concentrate and diluent for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Non-Hodgkin; Arthritis, Rheumatoid; Leukemia, Lymphocytic, Chronic, B-Cell | F.Hoffmann-LaRocheLtd. / F.Hoffmann-LaRocheLtd |
| Saudi Arabia | (L01FD01) trastuzumab | Ontruzant | 1 Vial, 150 mg, Intravenous use, Powder for concentrate for solution for infusion, 150mg , Vial, Powder for concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Stomach Neoplasms; Breast Neoplasms | SamsungBioepisCoLtd / PatheonItaliaS.P.A. |
| Saudi Arabia | (L01FD01) trastuzumab | Ontruzant | 1 Vial, 420 mg, Intravenous use, Powder for concentrate for solution for infusion, 420mg , Vial, Powder for concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Stomach Neoplasms; Breast Neoplasms | SamsungBioepisCoLtd / FAREVAPAU |
| Saudi Arabia | (L01FD01) trastuzumab | Trazimera | 1 Vial, 440 mg, Intravenous use, Powder for concentrate for solution for infusion, 440mg , Vial, Powder for concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Stomach Neoplasms; Breast Neoplasms | PFIZER / PfizerManufacturingBelgiumN.V. |
| Saudi Arabia | (L01FD01) trastuzumab | CANHERA | 1 Vial, 440 mg, Intravenous use, Powder and solvent for solution for injection, 440mg , Vial, Powder and solvent for solution for injection | Retail price without vat |
$0-0 |
$0-0 |
n/a | BioconBiologicsLimited / BioconLimited |
| Saudi Arabia | (L01FD01) trastuzumab | CANHERA 150MG VIAL | 1 Vial, 150 mg, Intravenous use, Infusion, 150mg , Vial, Infusion | Retail price without vat |
$0-0 |
$0-0 |
n/a | BioconBiologicsLimited / BioconLimited |
| Saudi Arabia | (L01FD01) trastuzumab | HERCEPTIN 120 mg/ml Solution For Injection | 1 Vial, 5ml, 120 mg/ml, Subcutaneous use, Solution for injection, 120mg/ml , Vial, Solution for injection | Retail price without vat |
$0-0 |
$0-0 |
Stomach Neoplasms; Breast Neoplasms | ROCHE / F.Hoffmann-LaRocheLtd. |
| Saudi Arabia | (L01FD01) trastuzumab | Trazimera | 1 Vial, 150 mg, Intravenous use, Powder for concentrate for solution for infusion, 150mg , Vial, Powder for concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Stomach Neoplasms; Breast Neoplasms | PFIZER / PfizerManufacturingBelgiumN.V. |
| Saudi Arabia | (L01FD01) trastuzumab | OGIVRI | 1 Vial, 420 mg, Intravenous use, Lyophilisate for solution for infusion, 420mg , Vial, Lyophilisate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Stomach Neoplasms; Breast Neoplasms | MylanPharmaGmbH / BioconLimited |
| Saudi Arabia | (L01XC06) cetuximab | Erbitux 500 mg per 100 ml | 1 Bottle, 100ml, 5 mg/ml, Intravenous use, Solution for infusion, 5mg/ml , Bottle, Solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Head and Neck Neoplasms; Colorectal Neoplasms | MerckEuropeBV / MERCKHEALTHCAREKGAA |
| Saudi Arabia | (L01XC06) cetuximab | Erbitux 100 mg per 20 ml | 1 Bottle, 20ml, 5 mg/ml, Intravenous use, Solution for infusion, 5mg/ml , Bottle, Solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Head and Neck Neoplasms; Colorectal Neoplasms | MerckEuropeBV / MERCKHEALTHCAREKGAA |
| Saudi Arabia | (L01XC12) brentuximab vedotin | ADCETRIS 50 mg powder for concentrate for solution for infusion | 1 Vial, 50 mg, Intravenous use, Powder for concentrate for solution for infusion, 50mg , Vial, Powder for concentrate for solution for infusion | Retail price without vat |
$0-0 |
$0-0 |
Lymphoma, Non-Hodgkin; Hodgkin Disease | TAKEDAPHARMAA/S / BSPPHARMACEUTICALS |
Pages
